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Multilocus Genetic Risk Scores for Venous Thromboembolism Risk
Assessment
Jose Manuel Soria, BSc, PhD; Pierre-Emmanuel Morange, MD, PhD; Joan Vila, PhD; Juan Carlos Souto, MD, PhD; Manel Moyano, BSc;
David-Alexandre Tregou€et, BSc, PhD; Jose Mateo, MD, PhD; Noemi Saut, BSc, PhD; Eduardo Salas, MD, PhD; Roberto Elosua, MD, PhD
Background-—Genetics plays an important role in venous thromboembolism (VTE). Factor V Leiden (FVL or rs6025) and
prothrombin gene G20210A (PT or rs1799963) are the genetic variants currently tested for VTE risk assessment. We
hypothesized that primary VTE risk assessment can be improved by using genetic risk scores with more genetic markers than
just FVL-rs6025 and prothrombin gene PT-rs1799963. To this end, we have designed a new genetic risk score called Thrombo
inCode (TiC).
Methods and Results-—TiC was evaluated in terms of discrimination (D of the area under the receiver operating characteristic
curve) and reclassiﬁcation (integrated discrimination improvement and net reclassiﬁcation improvement). This evaluation was
performed using 2 age- and sex-matched case–control populations: SANTPAU (248 cases, 249 controls) and the Marseille
Thrombosis Association study (MARTHA; 477 cases, 477 controls). TiC was compared with other literature-based genetic risk
scores. TiC including F5 rs6025/rs118203906/rs118203905, F2 rs1799963, F12 rs1801020, F13 rs5985, SERPINC1
rs121909548, and SERPINA10 rs2232698 plus the A1 blood group (rs8176719, rs7853989, rs8176743, rs8176750) improved
the area under the curve compared with a model based only on F5-rs6025 and F2-rs1799963 in SANTPAU (0.677 versus 0.575,
P<0.001) and MARTHA (0.605 versus 0.576, P=0.008). TiC showed good integrated discrimination improvement of 5.49 (P<0.001)
for SANTPAU and 0.96 (P=0.045) for MARTHA. Among the genetic risk scores evaluated, the proportion of VTE risk variance
explained by TiC was the highest.
Conclusions-—We conclude that TiC greatly improves prediction of VTE risk compared with other genetic risk scores. TiC should
improve prevention, diagnosis, and treatment of VTE. ( J Am Heart Assoc. 2014;3:e001060 doi: 10.1161/JAHA.114.001060)
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T hrombosis is the formation of a blood clot inside a bloodvessel that obstructs the normal ﬂow of blood. The
clinical manifestations of thrombosis are myocardial infarc-
tion, stroke, and venous thromboembolism (VTE). The latter
includes pulmonary embolism and deep vein thrombosis. VTE
is a common cardiovascular illness associated with high
mortality1 that affects 0.2% of the US and European
population annually.1,2 Consequently, it is a considerable
public health concern with a high economic burden.3,4
VTE is a multifactorial, complex disease that results from a
combination of genetic and acquired risk factors. The
heritability of VTE has been estimated at about 60%.5 The
genetic factors underlying the risk of thrombosis include
some well-established mutations such as the FVL and PT
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mutations, which give rise to deﬁcient anticoagulant or gain-
of-function proteins.6 In addition, recent evidence shows
several genetic variants that predispose someone to VTE by
modifying components in the coagulation pathway.7–15
Moreover, several common low-penetrance gene variants
and unsuspected genes have been identiﬁed by genomewide
association studies (GWASs) as contributing to a risk of
thromboembolic disease.16–18 These new variants still require
proper clinical validation.
This new knowledge of the genetic proﬁle of VTE could be
used to increase the ability to more accurately predict the
risk of a thrombotic event. In current clinical practice, only
FVL and PT mutations are used as markers to assess a
patient’s risk of VTE. In a genetic risk score (GRS) described
by de Haan et al,19 5 of 31 single nucleotide polymorphisms
(SNPs) linked to VTE were found to improve the predictive
capacity of clinical factors including family history assess-
ment. Moreover, the similar discriminative capacity observed
by these authors with the use of 5 of 31 SNPs associated
with VTE clearly indicates a need to identify an appropriate
panel of genetic variants and to determine the predictive
capacity of such a panel as a risk assessment score for this
complex disease.
Our study was designed to compare the predictive capacity
of a new GRS, Thrombo inCode (TiC), with a risk score based
on family history alone and another based on FVL and PT
mutations.
Methods
Study Populations
The SANTPAU case–control study, conducted on a Spanish
population, has been described extensively.20 Brieﬂy, 248
consecutive unrelated patients who had been referred to or
had visited the Hospital de la Santa Creu i Sant Pau
(Barcelona, Spain) for thrombophilia screening were
recruited over the period from November 1997 to April
2002. The inclusion criterion was having suffered a ﬁrst
thrombotic event at an age younger than 68 years. Patients
were excluded if they had cancer or a history of chronic or
acute liver disease or nephrotic syndrome. A medical history
was obtained for each patient, including the site of
thrombosis and acquired predisposing factors. The diagnosis
of deep vein thrombosis of the lower limbs was established
objectively by ultrasonography or ascending venography.
Pulmonary embolism was diagnosed by ventilation–perfusion
lung scanning, pulmonary angiography, or spiral computed
tomography. Intracranial venous thrombosis was diagnosed
by magnetic resonance imaging. A patient’s family history
was scored as positive if at least 1 other ﬁrst- or second-
degree family member had a venous thrombosis. As
controls, 249 unrelated, asymptomatic, and apparently
healthy persons were recruited with no personal history of
VTE or use of oral anticoagulants. The control group was
matched to the patient group for age and sex. To avoid
genetic stratiﬁcation, both the case and control groups were
recruited from the same geographical region; all participants
were white, and all their family names were Spanish. The
study protocol was approved by the hospital’s institutional
review board, and signed informed consent was obtained
from each patient.
The Marseille Thrombosis Association study (MARTHA)21 is
a case–control study including 1150 patients and 801
controls. The patients were unrelated and white; were
recruited consecutively from the Thrombophilia Center,
Ho^pital de la Timone (Marseille, France) over the period from
January 1994 to October 2005; had VTE; and were without
known risk factors including antithrombin, protein C or protein
S deﬁciency, homozygosity for FVL or for PT, or the presence
of lupus anticoagulant. Thrombotic events including deep vein
thrombosis and pulmonary embolism were documented by
venography, Doppler ultrasound, spiral computed tomo-
graphic scanning angiography, and/or ventilation–perfusion
lung scan. The control group was comprised of 2 subgroups:
one included 475 healthy French white subjects with no
personal history of cardiovascular disease (VTE was also
considered) who were from the Marseille area and another
group made up of 326 healthy French white heterozygotes for
the FV Leiden or FII 20210A variants. In the MARTHA case–
control study, controls were older than patients (47.4 versus
38.0 years, respectively), and the proportion of men was also
higher among controls than among patients (47.8% versus
30.1%, respectively). To avoid the paradoxical (and con-
founded, by design) protective association between age and
VTE and between sex and control, we matched patients and
controls 1:1 by age and sex. Patients and controls were
randomly matched 1:1 for the same sex and similar age
(5 years). In the original MARTHA study, 1148 patients and
801 controls were included, but for our study, we considered
477 cases and 477 controls.
SNP Selection and Genotyping
We performed a systematic review and meta-analysis to select
genetic variants that contribute to VTE risk (Table 1). Based on
this information, we deﬁned a panel, TiC (Table 1), with the
variants rs6025 (F5, Factor V Leiden), rs118203906 (F5,
Factor V Hong Kong), rs118203905 (F5, Factor V Cambridge),
rs1799963 (F2, G20210A), rs5985 (F13, V34L), rs121909548
(SERPINC1, 384 Ala>Ser), rs2232698 (SERPINA10,
67 ARG>Stop), and rs1801020 (F12, 46 C>T) and the
A1 carriers rs8176719, rs7853989, rs8176743, and
rs8176750.22 It is important to note that all of these
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genetic variants have functional effects on the coagulation
cascade.7–15 All except the A1 carriers are gain- or loss-of-
function variants.
In addition, 3 different panels of genetic variants were
deﬁned (Table 1):
1. FVL+PT: rs6025 (F5, Factor V Leiden) and rs1799963 (F2,
20210 G>A). This panel represents the genetic variants
most commonly tested in current clinical practice.
2. de Haan et al panel: rs6025 (F5, Factor V Leiden),
rs1799963 (F2, 20210 G>A), rs8176719 (AB0),
rs2066865 (FGG, 10034 C>T), and rs2036914 (F11,
7872 C>T).
3. Extended panel: All the TiC variants plus rs2289252 (F11,
22771 T>C), rs2036914 (F11, 7872 C>T), rs710446
(KNG1, Ile581Thr), and rs2066865 (FGG, 10034 C>T).
These SNPs were added because of their relationships to
VTE that were detected recently by GWAS.
DNA samples from the 2 populations were genotyped. With
the SANTPAU samples, the Thrombo inCode kit (Ferer inCode)
was used to identify the variants included in this panel, and
the remaining variants were detected by Taqman assays run
in an ABI 7500 instrument. The MARTHA samples were
genotyped by allele-speciﬁc polymerase chain reaction.
Genetic Risk Score
To take into account the association strengths between the
selected SNPs and VTE, we created a weighted GRS for each
of the panels described (Table 1). The weights assigned to
each SNP were deﬁned a priori and based on the results of
published meta-analyses in the case of FVL23 and PT24 or data
from individual reports for rs2232698,13,25 rs1801020,20,26,27
rs59852,8,28,29 rs2289252,30,31 and rs203691431,32 or
meta-GWAS for the variants rs2066865,19,33,34 AB0,35
rs121909548,14 and rs71044636 (Tables S1 and S2). For FV
Cambridge and Hong Kong, the same weights as FV Leiden
were assigned. For the panel described by de Haan et al,19 we
used the weights cited by the authors.
The genetic variants were introduced considering the
genetic risk, and all were weighted in the same direction. The
only genetic variant with a minor allele associated with lower
thrombosis risk and odds was rs5985; in this case, we
considered the common homozygote group as the risk.
Family History
For SANTPAU populations, data were compiled on the family
history of VTE.
Table 1. Genetic Variants Included in the Different Genetic Risk Scores Assessed and Coefﬁcients (Weights) Assigned to Each
Risk Factor
SNP Gene Mutation
Risk Coefﬁcient
Assigned (ß)
GRS*
1 2 3 4
rs6025, FV Leiden F5 R506Q 1.589
rs118203905, FV Hong Kong F5 R306G 1.589
rs118203906, FV Cambridge F5 R306T 1.589
rs1799963 F2 G20210A 0.293
ABO ABO A1 carriers 0.956
rs8176719 ABO —
rs1801020 F12 C46T 1.633
rs5985 F13 V34L 0.198
rs2232698 SERPINE10 R67X 1.358
rs121909548 SERPINC1 A384S 2.277
rs2036914 F11 0.293
0.519
rs2066865 FGG 0.344
rs710446 KNG1 0.182
rs2289252 F11 0.315
0.577
GRS indicates genetic risk score; SNP, single nucleotide polymorphism.
*GRS 1, FVL+PT based on F5 and rs1799963 (F2, prothrombin); GRS 2: Thrombo inCode based on F5, rs1799963 (F2, prothrombin), ABO-A1 carriers (rs8176719, rs7853989, rs8176743,
rs8176750), rs1801020, rs5985, rs2232698, and rs121909548; GRS 3, de Haan et al based on F5, rs1799963 (F2, prothrombin), ABO (rs8176719), rs2036914, and rs2066865; GRS 4,
expanded based on F5, rs1799963 (F2, prothrombin), ABO-A1 carriers (rs8176719, rs7853989, rs8176743, rs8176750), rs1801020, rs5985, rs2232698, rs121909548, rs2036914,
rs2066865, and rs2289252.
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Statistical Analysis
Continuous variables are designated as means and standard
deviations, and categorical variables are designated as
proportions. Odds ratios (ORs) for the different variables
linked to VTE and their 95% conﬁdence intervals were
calculated by conditional logistic regression.
We constructed different predictive models based on the
FVL+PT GRS, the TiC GRS, the de Haan et al GRS, the
extended GRS, or family history and combinations of these.
As previously mentioned, the weights assigned to all
variables included in the models were deﬁned a priori based
on prior evidence.
The different scores were assessed according to the
scientiﬁc statement of the American Heart Association, which
describes the steps to be taken to evaluate novel risk markers
in the cardiovascular ﬁeld.37
To assess whether the strengths of association between
clinical or genetic factors and thrombosis were different for
those observed in the literature (expected) and those we
observed in our study (observed), we compared coefﬁcients
(ie, logarithm of the ORs) by the z test statistic; in the
equation z=(b[E]b[0])/SE, b[E] and b[0] are, respectively,
the coefﬁcients expected and observed, whereas SE is the
standard error of the difference in the coefﬁcient.
We used different measures of performance to test the
quality of ﬁt in the GRS models. Discrimination measures the
ability of the model to discriminate between participants who
will and will not have a VTE. We quantiﬁed this by calculating
the area under the receiver operating characteristic curve.38
This value represents an estimate of the probability that a
model assigns a higher risk to those participants who will
have a VTE than to those who will not have a VTE.
Reclassiﬁcation measures how the inclusion of a new
marker classiﬁes as highest risk those participants with a VTE
and as lowest risk those without a VTE. We used the methods
described by Pencina et al.39,40 Integrated discrimination
improvement (IDI) considers changes in the estimated VTE
prediction probabilities as a continuous variable. The IDI
increases when a new marker is added and thus enhances the
estimate of the risk in those with VTE and decreases in those
without VTE. Similarly, net reclassiﬁcation improvement (NRI)
requires the classiﬁcation of the participants in risk categories
and considers changes in the predicted probabilities of
estimated VTE that imply a change from one category to
another. Risk categories required to estimate the net
reclassiﬁcation improvement were established according to
risk tertiles.
The sensitivity and speciﬁcity of the different GRSs were
calculated41 using the cut points giving the highest sensitivity.
All tests were performed using R statistical software
(version 3.0.1).42
Results
The sociodemographic, clinical, and genetic characteristics of
the participants are listed in Table 2. In both populations,
patients showed higher scores than controls in all of the GRSs
examined.
Regression coefﬁcients (ie, logarithm of the ORs) and their
standard errors for associations between the different
variables and VTE are shown in Table S3. In our case, not
all SNPs were associated with VTE, although we included all
SNPs in the GRS calculations because of consistent reports in
the literature of their correlation with VTE. In Table S3, we
also provide the expected regression coefﬁcients based on a
literature review and our own meta-analysis and P values for
differences between observed and expected coefﬁcients. We
did not observe a signiﬁcant difference between expected and
observed coefﬁcients except for mutations in the gene for FVL
in the MARTHA population (expected coefﬁcient 1.589 versus
observed 0.805, P=0.028).
As shown in Table 3, in the SANTPAU population, the
predictive model based on FVL and PT mutations showed an
area under the curve of 0.575 (95% CI 0.547 to 0.604), which
increased signiﬁcantly when the model was based on the TiC
GRS (0.575 versus 0.677, P<0.001). The de Haan et al GRS
also was signiﬁcantly better than the predicted model based
on FVL and PT mutations (0.575 versus 0.645, P=0.015);
however, this GRS did not improve the discriminative capacity
of TiC (0.677 versus 0.645; P=0.346). Moreover, when we
extended the TiC score (extended GRS) by adding 4 common
VTE-associated SNPs (F11 rs2289252 and rs2036914, KNG1
rs710446, and FGG rs2066865), no improvement was
observed over the TiC GRS area under the curve (0.677
versus 0.671, P=0.848).
The same approach was used to assess the validity and
predictive improvement capacity of the different models when
FVL and PT mutations (often used in clinical practice) were
considered in addition to family history of VTE. The results in
Table 4 indicate the capacity of each of the GRS models in
addition to family history of VTE to improve the discrimination
capacity when compared with family history of VTE alone. The
discriminative capacity of TiC plus family history of VTE was
not improved by the de Haan et al or extended GRSs plus
family history of VTE.
Reclassiﬁcation was improved by TiC, extended, or de
Haan et al GRS when compared with the FVL+PT model, as
measured by IDI (5.49, P<0.001; 2.56, P=0.009; and 2.43,
P=0.015, respectively) (Table 3). The only GRS showing an
improvement in reclassiﬁcation (net reclassiﬁcation improve-
ment) over the simple FVL+PT model was the TiC GRS (19.17,
P=0.002). Similar results were obtained when all GRSs plus
family history of VTE were compared with family history of
VTE alone (Table 4).
DOI: 10.1161/JAHA.114.001060 Journal of the American Heart Association 4
Venous Thromboembolism Risk Genetic Scores Soria et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on June 9, 2016http://jaha.ahajournals.org/Downloaded from 
In addition, using the GRS cut points to obtain maximal
sensitivity, the sensitivity of TiC in the SANTPAU population was
signiﬁcantly higher than that of FVL+PT (0.85 versus 0.20%,
respectively) (Table 5). The speciﬁcity of the FVL+PT GRS was
higher than that of TiC (0.95 versus 0.25, respectively).
More important, the variance in VTE risk explained by the
different GRSs in the SANTPAU population were 7.1%, 15.1%,
9.9%, and 13.0% for FVL+PT, TiC, de Haan et al, and extended
GRSs, respectively. It is noteworthy that the TiC score
explained the greatest amount of variance in thrombotic risk;
in fact, it was >2-fold the variance explained by the
conventional FVL+PT model.
Similar results were observed for the MARTHA population
(Table 3). The AUC increased signiﬁcantly with respect to the
model based on FVL and PT alone when we used the TiC
genetic variants (0.576 versus 0.605, P=0.008) and the
extended genetic model (0.576 versus 0.629, P=0.037);
however, the extended score did not improve the discrimina-
tive capacity of TiC (0.605 versus 0.629, P=0.361). Moreover,
the de Haan et al GRS offered no improvement over the
discriminative capacity of FVL+PT (0.576 versus 0.594,
Table 2. Main Sociodemographic, Clinical, and Genetic
Characteristics of the Study Participants
Controls Cases P Value
n=249 n=248
SANTPAU
Sex (male), n (%) 109 (44.0) 111 (44.6) 0.960
Age (y), mean (SD) 49.0 (14.9) 47.1 (14.0) 0.145
Smoker, n (%) 101 (40.7) 108 (43.7) 0.559
Diabetes, n (%) 9 (3.7) 14 (5.7) 0.404
Oral contraceptives, n (%) 74 (29.8) 83 (33.5) 0.440
Family history, n (%) 45 (23.2) 97 (40.9) <0.001
F5 *†, n (%) 5 (2.02) 32 (12.9) <0.001
F2: rs1799963*, n (%) 7 (2.82) 19 (7.63) 0.027
ABO-A1 carriers/ABO*,
n (%)
87 (35.7) 147 (59.0) <0.001
F12: rs1801020*, n (%) 5 (2.02) 15 (6.02) 0.041
F13: rs5985*, n (%) 139 (56.5) 146 (58.6) 0.698
SERPINE10: rs2232698*,
n (%)
4 (1.61) 10 (4.02) 0.178
SERPINC1: rs121909548*,
n (%)
1 (0.40) 4 (1.61) 0.372
F11: rs2036914
Hetero, n (%) 111 (46.2) 119 (48.0) 0.77
Homo, n (%) 54 (22.5) 43 (17.3) 0.189
FGG: rs2066865*, n (%) 92 (37.9) 98 (39.4) 0.804
KNG1: rs710446b‡, n (%) 47 (19.5) 49 (19.8) 0.966
F11: rs2289252
Hetero, n (%) 113 (47.1) 122 (49.4) 0.675
Homo, n (%) 39 (16.2) 46 (18.6) 0.568
GRS 1§, mean (SD) 0.04 (0.23) 0.23 (0.54) <0.001
GRS 2§, mean (SD) 0.56 (0.61) 1.10 (0.89) <0.001
GRS 3§, mean (SD) 0.78 (0.56) 1.16 (0.76) <0.001
GRS 4§, mean (SD) 1.23 (0.66) 1.76 (0.95) <0.001
MARTHA n=477 N=477
Sex (male), n (%) 198 (41.5) 198 (41.5) 1.000
Age (years), mean (SD) 44.2 (13.6) 43.9 (14.0) 0.681
Smoker, n (%) 143 (30.2) 124 (27.7) 0.447
BMI (kg/m2), mean (SD) 23.8 (3.8) 25.0 (4.2) <0.001
Oral contraceptives, n (%) 105 (22.1) 187 (39.4) <0.001
F5 *†, n (%) 103 (21.6) 168 (35.2) <0.001
F2: rs1799963*, n (%) 92 (19.3) 86 (18.0) 0.678
ABO-A1 carries/ABO*, n (%) 28 (5.87) 47 (9.85) 0.030
F12: rs1801020*, n (%) 20 (4.19) 29 (6.08) 0.241
F13: rs5985*, n (%) 255 (53.5) 283 (59.3) 0.078
Continued
Table 2. Continued
Controls Cases P Value
SERPINE10: rs2232698*, n (%) 8 (1.68) 15 (3.14) 0.205
SERPINC1: rs121909548*,
n (%)
3 (0.63) 1 (0.21) 0.324
F11: rs2036914
Hetero, n (%) 231 (49.7) 236 (50.1) 0.948
Homo, n (%) 118 (25.4) 100 (21.2) 0.155
FGG: rs2066865*, n (%) 178 (38.3) 220 (49.5) 0.001
KNG1: rs710446b‡, n (%) 92 (19.6) 82 (18.2) 0.638
F11: rs2289252
Hetero, n (%) 231 (48.4) 225 (47.2) 0.746
Homo, n (%) 72 (15.1) 126 (26.4) <0.001
GRS 1§, mean (SD) 0.40 (0.63) 0.61 (0.73) <0.001
GRS 2§, mean (SD) 0.67 (0.83) 0.97 (0.92) <0.001
GRS 3§, mean (SD) 0.85 (0.73) 1.12 (0.83) <0.001
GRS 4§, mean (SD) 1.34 (0.86) 1.70 (0.94) <0.001
BMI indicates body mass index; GRS, genetic risk score; hetero, heterozygosis; homo,
homozygosis.
*Carriers of the risk allele.
†Carrier of any risk allele (Leiden, Hong Kong, or Cambridge).
‡Homozygotes for the risk allele.
§GRS 1, FVL+PT based on F5 and rs1799963 (F2, prothrombin); GRS 2, Thrombo inCode
based on F5, rs1799963 (F2, prothrombin), ABO-A1 carriers, rs1801020, rs5985,
rs2232698, and rs121909548; GRS 3, de Haan et al based on F5, rs1799963 (F2,
prothrombin), ABO, rs2036914, rs2066865; GRS 4, expanded based on F5, rs1799963
(F2, prothrombin), ABO, rs1801020, rs5985, rs2232698, rs121909548, rs2036914,
rs2066865, and rs2289252; ABO-A1 carriers: rs8176719, rs7853989, rs8176743,
rs8176750; ABO: rs8176719.
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P=0.47). In addition, when analyzing the reclassiﬁcation, only
the TiC score improved the reclassiﬁcation capacity of
FVL+PT, as assessed by the IDI (0.96, P=0.045).
The sensitivity and speciﬁcity of TiC scores were similar in
the MARTHA population (0.850 and 0.264, respectively);
however, the sensitivity and speciﬁcity of the FVL+PT GRS in
the MARTHA population differed from that found in the
SANTPAU population (sensitivity 0.532 and speciﬁcity 0.591
in MARTHA).
It should be emphasized that in the MARTHA study, the
extended GRS explained a high proportion of the variance in
VTE risk (5.3%), whereas the FVL+PT, TiC, and de Haan et al
Table 3. Predictive Capacities of the Different Models and Improvements Observed Including Different Genetic Variants Compared
With the Simplest Model (FVL+PT)
GRS 1
FVL+PT (95% CI)
GRS 2
TiC (95% CI)
GRS 3
de Haan et al (95% CI)
GRS 4
Extended (95% CI)
SANTPAU
Discrimination
AUC 0.575 (0.547; 0.604) 0.677 (0.631; 0.724) 0.645 (0.596; 0.694) 0.671 (0.623; 0.719)
P value DAUC NA <0.001 0.015 <0.001
Reclassification
IDI NA 5.49 (3.35; 7.63) 2.43 (0.47; 4.39) 2.57 (0.65; 4.49)
P value NA <0.001 0.015 0.009
NRI NA 19.17 (7.01; 31.33) 5.76 (21.84; 10.32) 8.66 (25.61; 8.29)
P value NA 0.002 0.483 0.317
MARTHA
Discrimination
AUC 0.576 (0.544; 0.609) 0.605 (0.570; 0.640) 0.594 (0.557; 0.631) 0.629 (0.592; 0.665)
P value DAUC NA 0.008 0.478 0.037
Reclassification
IDI NA 0.96 (0.02; 1.90) 0.06 (0.86;0.75) 0.19 (0.88; 1.25)
P value NA 0.045 0.889 0.730
NRI NA 4.94 (1.46; 11.33) 5.98 (13.98; 2.02) 7.11 (16.35; 2.13)
P value NA 0.130 0.143 0.131
AUC indicates area under the receiver operating characteristic curve; GRS, genetic risk score; IDI, integrated discrimination improvement; NA, not applicable; NRI, net reclassiﬁcation
improvement; TiC, Thrombo inCode.
Table 4. Predictive Capacity of the Different Models and Improvements Observed When Including Different Genetic Variants With
Respect to Family History in the SANTPAU Population
Family History (95% CI)
GRS 1
FVL+PT (95% CI)
GRS 2
TiC (95% CI)
GRS 3
de Haan (95% CI)
GRS 4
Extended (95% CI)
Discrimination
AUC 0.589 (0.545; 0.632) 0.647 (0.602; 0.691) 0.701 (0.652; 0.749) 0.684 (0.633; 0.734) 0.700 (0.649; 0.750)
P value DAUC NA <0.001 <0.001 0.005 0.001
Reclassification
IDI NA 3.43 (2.10; 4.76) 6.63 (4.45; 8.82) 4.28 (2.18; 6.38) 2.57 (0.40; 4.74)
P value NA <0.001 <0.001 <0.001 0.020
NRI NA 16.04 (9.50; 22.57) 29.42 (14.33; 44.53) 6.92 (11.40; 25.24) 0.65 (18.57; 19.88)
P value NA <0.001 <0.001 0.459 0.947
AUC indicates area under the receiver operating characteristic curve; GRS, genetic risk score; IDI, integrated discrimination improvement; NA, not applicable; NRI, net reclassiﬁcation
improvement; TiC, Thrombo inCode.
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GRSs explained 3.1%, 3.9%, and 3.7%, respectively. This
observation could be attributable to the fact that the extended
panel included the genetic variants included in TiC plus 4
common SNPs (F11 rs2289252 and rs2036914, KNG1
rs710446, and FGG rs2066865) reported to be associated
with VTE in the MARTHA study.
Discussion
As knowledge of disease improves, new biomarkers and new
tests are changing the traditional concept of risk assessment.
Given that thrombosis is the ﬁnal outcome of many systemic
disorders, it is not surprising that interest in this disease is
increasing rapidly; however, accurately predicting a person’s
risk of developing a complex disease is very difﬁcult. This
difﬁculty results, in large measure, from the many risk factors
that exist for a given disease. Most of these factors and their
interactions are unknown. VTE is a case in point because it
has a large number of risk factors related to genetic
variability.5 Despite this substantial genetic component of
VTE and the new knowledge generated by GWASs, only 2 of
these variants—FVL and PT—are used conventionally in
clinical settings worldwide.
In our study, we assessed the predictive validity of 3 GRSs
in 2 independent populations (SANTPAU and MARTHA)
according to the American Heart Association’s guidelines for
the evaluation of novel cardiovascular risk markers.37 The
proof of concept derived from our study is that the FVL+PT
model can be greatly improved by using new genomic
information. More important, by comparing the use of 3
GRSs on the same populations, we were able to show
conclusively that their predictive capacities are greatly
augmented using the TiC GRS.
In an initial step, we performed a systematic review of the
literature and meta-analysis to select genetic variants that
contribute to VTE risk, and we assigned these variants a
corresponding VTE risk coefﬁcient (Tables 1, S1, and S2). The
genetic variants selected have a direct functional effect
on the blood-clotting proteins,7–15 highlighting the role of
coagulation in thrombosis risk. Based on these selected
genetic variants, we deﬁned 3 weighted GRSs and determined
whether they could assess the risk of VTE better than a model
based on family history or FVL+PT alone. The weights
assigned to each genetic variant were deﬁned a priori and
based on the literature.
In the second step of our study, we selected 2 indepen-
dent populations in which to compare the performance of
these genetic scores: the Spanish population examined in
the SANTPAU case–control study and the population of the
French MARTHA study, with cases and controls that were
rich in FV Leiden or FII 20210A mutations. Accordingly,
the SANTPAU study participants better represented the
general white population and formed the basis of our study,
whereas the MARTHA study participants were considered a
stricter sample in which to assess the role of new genetic
markers because the effects of FV Leiden and FII mutations
were overrepresented.
In this study, we were able to conﬁrm the prior ﬁnding that
FVL+PT improves the VTE predictive capacity of family
history.43 We were also able to demonstrate that TiC, a GRS
including 12 low-frequency, high-impact genetic risk factors,
was the only score of the 3 examined that signiﬁcantly
improved the VTE predictive capacity of family history of VTE
(Table 4) and FVL+PT (Table 3). This improvement consisted
of better discrimination and reclassiﬁcation in both the
SANTPAU and MARTHA study populations.
One of the GRSs that we examined was reported by de
Haan et al.19 Remarkably, these authors observed that a risk
score including 31 SNPs independently associated with a
VTE risk through GWAS showed a similar predictive capacity
to a score including only 5 of these SNPs (FVL, PT, ABO
blood group, FGG gene rs2066865, and F11 gene
rs2289252). Three of these 5 genetic variants (FVL, PT,
ABO blood group) reported by de Haan et al were included in
the TiC score. Importantly, these matching markers are low-
frequency variants that show the highest individual ORs for
VTE risk. This fact clearly indicates the limited value of risk
scores composed of common SNPs that show low individual
ORs, such as those identiﬁed by GWAS, when low-frequency
variants with high ORs are also considered. In effect, the
addition of 4 common SNPs (rs710446, rs2289252,
rs2066865 and rs2036914) identiﬁed through GWAS to
TiC (extended GRS) failed to improve the area under the
curve.
This point is important regarding GWASs because the
ﬁndings of both the study by de Haan et al and our study
indicate the better predictive capacity of a GRS that considers
low- frequency variants that returns high ORs. It should be
underscored that the TiC includes rare variants featuring high
individual ORs (eg, SERPINC1 gene rs121909548 and
SERPIN10 gene rs2232698 polymorphisms). Based on these
results and in agreement with a previous GWAS,21 it is
Table 5. Clinical Utility (Measured as the Sensitivity) and
Speciﬁcity of TiC Compared With FVL+PT in the SANTPAU and
MARTHA Populations
Selected
GRS Cut
Points
SANTPAU MARTHA
Sensitivity Speciﬁcity Sensitivity Speciﬁcity
FV+PT 0.147 0.20 0.95 0.53 0.59
TiC 0.099 0.85 0.25 0.85 0.26
GRS indicates genetic risk scores; TiC, Thrombo inCode.
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unlikely that common risk alleles identiﬁed through GWAS
(showing a Minon Allele Frequency [MAF] >0.05 and a
modestly increased VTE risk with an OR in the range 1.10 to
1.35) alone account for a large proportion of the familial risk
of VTE and its clinical variability, as observed for most other
human diseases investigated through GWASs.44
These ﬁndings emphasize the need to pay special attention
to low-frequency or rare variants rendering high ORs. In a
recent study, the beneﬁts of an in-depth sequencing strategy
were emphasized because it permitted the identiﬁcation of a
rare mutation responsible for familial cases of early-onset
VTE.45,46 The important predisposing role played by low-
frequency or rare variants in VTE was highlighted in a study
based on multigenerational data by Z€oller et al,47 who
observed a high familial risk of VTE in a small number of
siblings, suggesting segregation of rare but strong genetic risk
factors.
In our study, the clinical utility (measured as the sensitivity
of the GRSs) of the TiC GRS compared with FVL+PT was also
examined. Using the cut point obtaining the highest sensitivity
for FVL+PT, the sensitivity of FVL+PT was 0.20 and 0.53 of
patients with VTE in SANTPAU and MARTHA, respectively,
whereas using TiC at the cut point for maximal sensitivity, the
sensitivity of TiC was 0.85 and 0.85 in SANTPAU and
MARTHA, respectively. High sensitivity is important when the
test is used to identify a serious but preventable or treatable
disease such as VTE.41 This is especially true when low
speciﬁcity may represent a genetic predisposition to VTE that
will lead to VTE only when pro-VTE clinical conditions are also
present. The identiﬁcation of genetic thrombophilia has
several clinical applications because most guidelines48 advo-
cate assigning a moderate risk of VTE in patients with
thrombophilia.
Although our results point to a clear association between
GRS and the risk of VTE, they should be interpreted with
caution because of the limitations of our study. First, we did
not include clinical data (apart from family history) in the
scores because, as indicated by the guidelines,46 several
clinical scenarios exist for VTE but the genetic basis of the
disease is common to all of them. Consequently, we focused
our study on genetic factors and will be examining the use of
the TiC GRS in combination with several clinical variables in
future studies. This strategy of combining genetic and clinical
data, as observed by de Haan et al,19 is likely to further
improve the performance of TiC, especially its sensitivity,
speciﬁcity, and the area under the receiver operating
characteristic curve.
Given the lack of universally acceptable risk categories for
VTE, in our net reclassiﬁcation improvement analysis, we
established categories based on risk tertiles, which could be
an overly demanding process. Nevertheless, this limitation
was resolved using the IDI index, which measures risk as a
continuum and thus should be considered a more powerful
indicator for reclassiﬁcation in our study.
Although we have described the differences in the design
of the 2 populations, the differences in the predictive
capacities of the TiC GRS in those 2 populations may raise
concerns about the replicability of TiC in other populations.
As mentioned, MARTHA has a special design to put the new
markers under additional stress to evaluate whether they add
value to FVL+PT. It is a case–control study enriched in
carriers of FVL and PT mutations, for which >50% of
participants are carriers of 1 of these genetic variants. It is
expected that the area under the receiver operating charac-
teristic curve and the IDI and net reclassiﬁcation improve-
ment results could be modest when comparing TiC with
FVL+PT because these 2 mutations account for an important
part of the risk, especially if half of the participants are
carriers. Despite this big effect of these 2 mutations (due to
the study design), it is important to emphasize that TiC also
signiﬁcantly improved the predictive capacity of FVL+PT in
MARTHA population. Moreover, we must consider the
sensitivity and speciﬁcity of TiC because those classiﬁcation
functions, contrary to other statistical functions, are more
strongly associated with the capacity of the test than with
the speciﬁc characteristic of the population in which it is
tested.41 The sensitivity and sensibility of TiC were the same
in the SANTPAU and MARTHA populations (sensitivity 0.85
for both; speciﬁcity 0.25 versus 0.26 in SANTPAU and
MARTHA, respectively). This supports the idea that TiC will
have similar performance in other populations. Considering
the number, weight, and pathological relevance of the
genetic variants included in TiC, the signiﬁcant improvement
in area under the received operating character curve and IDI
in MARTHA, and the similar sensitivity and speciﬁcity in both
populations, it is reasonable to believe that TiC will be
replicable.
Finally, replication of the present results in other popula-
tions, evaluation of the clinical utility (measured as reduction
in VTE events by the use of TiC GRS), and analysis of the cost-
effectiveness of TiC remain to be accomplished.
In summary, to the best of our knowledge, this study is the
ﬁrst to assess the efﬁciency of new genetic markers of VTE,
such as TiC, according to the recommendations of experts in
the ﬁeld of cardiovascular disease.37 By determining the
discrimination and reclassiﬁcation capacity of these markers
and their clinical utility (measured as sensitivity) in compar-
ison to conventional recognized risk models (FVL+PT or family
history), we were able to conclude that by using new genetic
markers, especially TiC, conventional VTE risk assessment
algorithms are substantially improved. New risk scores such
as the TiC GRS, proposed in this paper, should allow for more
tailored thromboprophylaxis strategies and improve estimates
of a patient’s risk of VTE.
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Table 1. Genetic variants included in the different genetic risk scores (GRS) assessed: coefficients (weights) assigned to each genetic risk factor, 
and allele frequency and Hardy-Weinberg equilibrium (H-W) data obtained in the two studies, Sant Pau and MARTHA. 
      GRS  SANT PAU  MARTHA  
SNP Gene Mutation Genetic 
risk group* 
Risk 
coefficient 
assigned 
1 2 3 4 Rare allele 
Frequency 
H-W Rare 
allele 
frequency 
H-W 
rs6025 F5 Leiden R506 A carriers 1.589     0.01 0.873 0.11 0.008 
rs118203905 F5 Hong Kong F5 Hong 
Kong 
A carriers 1.589       0.00 0.982 
rs118203906 F5 Cambridge F5 Cambridge C carriers 1.589       0.00 --- 
rs1799963 F2 G20210A A carriers 0.293     0.01 0.822 0.10 0.020 
ABO** ABO  A1 carriers 0.956         
rs8176719 ABO   --       0.36 0.262 
rs1801020 F12 C46T TT homoz. 1.633     0.21 0.033 0.23 0.223 
rs5985 F13 V34L GG homoz. 0.198     0.25 0.832 0.27 0.929 
rs2232698 SERPINE10 R67X T carriers 1.358     0.01 0.898 0.01 0.854 
rs121909548 SERPINC1 A384S T carriers 2.277     0.00 0.975 0.00 0.945 
rs2036914 FXI  CT heter. 
TT homoz. 
0.293 
0.519 
    0.46 0.293 0.50 0.890 
rs2066865 FGG  TT homoz. 0.344     0.21 0.739 0.23 0.028 
rs710446 KNG1  CC homoz. 0.182     0.44 0.831 0.42 0.131 
rs2289252 FXI  CT heter. 
TT homoz. 
0.315 
0.577 
    0.40 0.788 0.40 0.655 
 
*Homoz.=Homozygous; Heter.=Heterozygous.  ** ABO: A1 carriers (rs8176719, rs7853989, rs8176743, rs8176750) 
 
 
 
Table 2: Data sources and results of the meta-analyses undertaken by the authors to assign a risk coefficient to each variant included in the 
genetic risk score. 
 Gen Reference Number of cases Number of controls OR Lower 
confidence 
interval 
Upper 
confidence 
interval 
Risk Coefficient 
assigned 
rs6025-FVL F5 1      1.589 
rs118203905-F5 Hong-Kong F5       1.589 
rs118203906-F5 Cambridge F5       1.589 
rs1799963 F2 2      0.293 
AB0 AB0 3      0.956 
rs8176719 AB0 3,4       
rs1801020 F12        
  5 250 250 4.82 1.50 15.60  
  6 -- -- 4.57 1.55 13.40  
  7 32463 32463 5.99 2.10 17.30  
Meta-analysis     5.12   1.633 
rs5985 F13        
  8 221 254 0.63 0.38 0.82  
  9 3165 4909 0.85 0.77 0.95  
  10 475 475 0.80 0.60 1.00  
Meta-analysis     0.82   -0.198 (0.198)* 
rs2232698 SERPINE10        
  11 1018 1018 3.35 1.30 8.60  
  12 250 250 5.70 1.25 26.0  
Meta-analysis     3.89   1.358 
rs121909548 SERPINC1 13       
rs2036914 F11        
Bezemer (2008) : Heteroz.  14 1314 2877 1.38 1.17 1.64  
Homoz. 1.71 1.43 2.05 
Austin (2011) : Heteroz.  15 1076 1239 1.20 0.92 1.70  
Homoz. 1.60 1.20 2.30 
Meta-analysis: Heteroz.     1.34   0.293 
Homoz. 1.68 0.519 
rs2066865 FGG 16, 17, 18      0.344 
rs710446 KNG1 19      0.182 
rs2289252 F11       0.315 
         0.577 
Arellano (2010) : Heteroz.  20 3921 4634 1.37 1.24 1.51  
Homoz. 1.78 1.57 2.01 
Austin (2011): Heteroz.  21 1076 1239 1.40 1.10 1.80  
Homoz. 1.80 1.30 2.50 
Meta-analysis: Heteroz.     1.37   0.315 
Homoz. 1.78 0.577 
*In the case of the variant rs5985, the rare variant wasassociatedwithlowerprobabilitye of presenting a VTE. To build the GRS the common variant wasconsidered to 
beassociatedwith a higherprobability of presenting of VTE. 
 
 
 
 
 
Table 3. Observed and expected strengths of associations between selected clinical or genetic factors and venous thromboembolic events and 
p-values for the differences between observed and expected values. 
  SANT PAU MARTHA 
 Expected 
coefficients 
Observed  Observed  
 Coefficients Standard 
Error 
p-value * Coefficients Standard 
Error 
p-value* 
Family History 1.185 0.711 0.240 0.323 NA NA NA 
F5** † 1.589 2.803 0.755 0.421 0.805 0.178 0.028 
F2- rs1799963 † 0.293 0.773 0.489 0.624 0.378 0.199 0.831 
ABO (A1)† 0.956 0.997 0.224 0.927 0.428 0.280 0.346 
F12- rs1801020 † 1.633 0.859 0.621 0.533 0.305 0.345 0.054 
F13- rs5985 † 0.198 -0.078 0.224 0.538 0.171 0.152 0.929 
SERPINE10- rs2232698 † 1.358 0.937 0.753 0.780 0.572 0.502 0.434 
SERPINC1- rs121909548 † 2.277 1.476 1.174 0.733 -0.983 1.264 0.197 
F11- rs2036914  Hetero 0.293 -0.039 0.273 0.543 0.228 0.207 0.875 
Homo 0.519 0.028 0.395 0.534 0.206 0.258 0.544 
 
FGG- rs2066865 † 0.344 -0.095 0.227 0.334 0.328 0.151 0.958 
KNG1- rs710446b ‡ 0.182 -0.206 0.278 0.485 -0.086 0.190 0.481 
F11- rs2289252  Hetero 0.315 0.186 0.299 0.829 0.191 0.190 0.744 
Homo 0.577 -0.017 0.403 0.461 0.965 0.262 0.459 
        
*for the difference between observed and expected coefficients. 
 
** Carrier of any risk allele (Leiden, Hong-Kong or Cambridge). 
NA indicates not applicable. 
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Table 1. Genetic variants included in the different genetic risk scores (GRS) assessed: coefficients (weights) assigned to each genetic risk factor, 
and allele frequency and Hardy-Weinberg equilibrium (H-W) data obtained in the two studies, Sant Pau and MARTHA. 
      GRS  SANT PAU  MARTHA  
SNP Gene Mutation Genetic 
risk group* 
Risk 
coefficient 
assigned 
1 2 3 4 Rare allele 
Frequency 
H-W Rare 
allele 
frequency 
H-W 
rs6025 F5 Leiden R506 A carriers 1.589     0.01 0.873 0.11 0.008 
rs118203905 F5 Hong Kong F5 Hong 
Kong 
A carriers 1.589       0.00 0.982 
rs118203906 F5 Cambridge F5 Cambridge C carriers 1.589       0.00 --- 
rs1799963 F2 G20210A A carriers 0.293     0.01 0.822 0.10 0.020 
ABO** ABO  A1 carriers 0.956         
rs8176719 ABO   --       0.36 0.262 
rs1801020 F12 C46T TT homoz. 1.633     0.21 0.033 0.23 0.223 
rs5985 F13 V34L GG homoz. 0.198     0.25 0.832 0.27 0.929 
rs2232698 SERPINE10 R67X T carriers 1.358     0.01 0.898 0.01 0.854 
rs121909548 SERPINC1 A384S T carriers 2.277     0.00 0.975 0.00 0.945 
rs2036914 FXI  CT heter. 
TT homoz. 
0.293 
0.519 
    0.46 0.293 0.50 0.890 
rs2066865 FGG  TT homoz. 0.344     0.21 0.739 0.23 0.028 
rs710446 KNG1  CC homoz. 0.182     0.44 0.831 0.42 0.131 
rs2289252 FXI  CT heter. 
TT homoz. 
0.315 
0.577 
    0.40 0.788 0.40 0.655 
 
*Homoz.=Homozygous; Heter.=Heterozygous.  ** ABO: A1 carriers (rs8176719, rs7853989, rs8176743, rs8176750) 
 
 
 
Table 2: Data sources and results of the meta-analyses undertaken by the authors to assign a risk coefficient to each variant included in the 
genetic risk score. 
 Gen Reference Number of cases Number of controls OR Lower 
confidence 
interval 
Upper 
confidence 
interval 
Risk Coefficient 
assigned 
rs6025-FVL F5 1      1.589 
rs118203905-F5 Hong-Kong F5       1.589 
rs118203906-F5 Cambridge F5       1.589 
rs1799963 F2 2      0.293 
AB0 AB0 3      0.956 
rs8176719 AB0 3,4       
rs1801020 F12        
  5 250 250 4.82 1.50 15.60  
  6 -- -- 4.57 1.55 13.40  
  7 32463 32463 5.99 2.10 17.30  
Meta-analysis     5.12   1.633 
rs5985 F13        
  8 221 254 0.63 0.38 0.82  
  9 3165 4909 0.85 0.77 0.95  
  10 475 475 0.80 0.60 1.00  
Meta-analysis     0.82   -0.198 (0.198)* 
rs2232698 SERPINE10        
  11 1018 1018 3.35 1.30 8.60  
  12 250 250 5.70 1.25 26.0  
Meta-analysis     3.89   1.358 
rs121909548 SERPINC1 13       
rs2036914 F11        
Bezemer (2008) : Heteroz.  14 1314 2877 1.38 1.17 1.64  
Homoz. 1.71 1.43 2.05 
Austin (2011) : Heteroz.  15 1076 1239 1.20 0.92 1.70  
Homoz. 1.60 1.20 2.30 
Meta-analysis: Heteroz.     1.34   0.293 
Homoz. 1.68 0.519 
rs2066865 FGG 16, 17, 18      0.344 
rs710446 KNG1 19      0.182 
rs2289252 F11       0.315 
         0.577 
Arellano (2010) : Heteroz.  20 3921 4634 1.37 1.24 1.51  
Homoz. 1.78 1.57 2.01 
Austin (2011): Heteroz.  21 1076 1239 1.40 1.10 1.80  
Homoz. 1.80 1.30 2.50 
Meta-analysis: Heteroz.     1.37   0.315 
Homoz. 1.78 0.577 
*In the case of the variant rs5985, the rare variant wasassociatedwithlowerprobabilitye of presenting a VTE. To build the GRS the common variant wasconsidered to 
beassociatedwith a higherprobability of presenting of VTE. 
 
 
 
 
 
Table 3. Observed and expected strengths of associations between selected clinical or genetic factors and venous thromboembolic events and 
p-values for the differences between observed and expected values. 
  SANT PAU MARTHA 
 Expected 
coefficients 
Observed  Observed  
 Coefficients Standard 
Error 
p-value * Coefficients Standard 
Error 
p-value* 
Family History 1.185 0.711 0.240 0.323 NA NA NA 
F5** † 1.589 2.803 0.755 0.421 0.805 0.178 0.028 
F2- rs1799963 † 0.293 0.773 0.489 0.624 0.378 0.199 0.831 
ABO (A1)† 0.956 0.997 0.224 0.927 0.428 0.280 0.346 
F12- rs1801020 † 1.633 0.859 0.621 0.533 0.305 0.345 0.054 
F13- rs5985 † 0.198 -0.078 0.224 0.538 0.171 0.152 0.929 
SERPINE10- rs2232698 † 1.358 0.937 0.753 0.780 0.572 0.502 0.434 
SERPINC1- rs121909548 † 2.277 1.476 1.174 0.733 -0.983 1.264 0.197 
F11- rs2036914  Hetero 0.293 -0.039 0.273 0.543 0.228 0.207 0.875 
Homo 0.519 0.028 0.395 0.534 0.206 0.258 0.544 
 
FGG- rs2066865 † 0.344 -0.095 0.227 0.334 0.328 0.151 0.958 
KNG1- rs710446b ‡ 0.182 -0.206 0.278 0.485 -0.086 0.190 0.481 
F11- rs2289252  Hetero 0.315 0.186 0.299 0.829 0.191 0.190 0.744 
Homo 0.577 -0.017 0.403 0.461 0.965 0.262 0.459 
        
*for the difference between observed and expected coefficients. 
 
** Carrier of any risk allele (Leiden, Hong-Kong or Cambridge). 
NA indicates not applicable. 
 
References: 
 
1. Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Factor V Leiden and the risk for venous 
thromboembolism in the adult Danish population. Ann Intern Med. 2004;140:330-337. 
2. Wu O, Robertson L, Twaddle S, Lowe G, Clark P, Walker I, Brenkel I, Greaves M, Langhorne P, Regan L, Greer I; 
Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Screening for thrombophilia 
in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol. 2005;131:80-90. 
3. Tirado I, Mateo J, Soria JM, Oliver A, Martínez-Sánchez E, Vallvé C, Borrell M, Urrutia T, Fontcuberta J. The ABO 
blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost. 
2005;93:468-474. 
4. De Haan HG, Bezemer ID, Doggen CJM, Le Cessie S, Reitsma PH, Arellano AR, Tong CH, Devlin JJ, Bare LA, 
Rosendaal FR, Vossen CY. Multiple SNP testing improves risk prediction of first venous thrombosis. Blood. 
2012;120:656-663. 
5. Tirado I, Soria JM, Mateo J, Oliver A, Souto JC, Santamaria A, Felices R, Borrell M, Fontcuberta J. Association 
after linkage analysis indicates that homozygosity for the 46C>T polymorphism in the F12 gene is a genetic risk factor for 
venous thrombosis. Thromb Haemost. 2004;91:899-904 
6. Reuner KH, Jenetzky E, Aleu A, Litfin F, Mellado P, Kloss M, Jüttler E, Grau AJ, Rickmann H, Patscheke H, Lichy 
C. Factor XII c46T genepolymorphism and the risk of cerebral venous thrombosis. Neurology. 2008;70:129-132. 
7. Cochery-Nouvellon E, Mercier E, Lissalde-Lavigne G, Daurès JP, Quéré I, Dauzat M, Marès P, Gris JC. 
Homozygosity for the C46T polymorphism of the F12 gene is a risk factor for venous thrombosis during the first 
pregnancy. J Thromb Haemost. 2007;5:700-707. 
8.  Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in 
the factor XIII gene with venous thrombosis. Blood. 1999;93:906-908. 
9. Wells PS, Anderson JL, Scarvelis DK, Doucette SP, Gagnon F. Factor XIII Val34Leu variant is protective against 
venous thromboembolism: a HuGE review and meta-analysis. Am J Epidemiol. 2006;164:101-109. 
10.  Van HylckamaVlieg A, Komansin N, Ariëns RAS, Poort SR, Grant PJ, Bertina RM, Rossendaal FR. Factor XIII 
Val34Leu polymorphism, facor XIII antigen levels and activity and the risk of deep venous thrombosis. BJH. 
2002;119:169-175. 
11. Corral J, Gonzalez-Conejero R, Soria JM, Gonzalez-Porras JR, Pérez-Ceballos E, Lecumberri R, Roldán V, Souto 
JC, Miñano A, Hernández- Espinosa D, Alberca I, Fontcuberta J, Vicente V. A nonsense polymorphism in the protein Z-
dependent protease inhibitor increases the risk for venous thrombosis. Blood. 2006;108:177-183. 
12. Van de Water N, Tan T, Ashton F, O´Grady A, Day T, Browett P, Ockelford P, Harper P. Mutations within the 
protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of 
thrombophilia. Br J Haematol. 2004;127:190-194. 
13. Corral J, Hernandez-Espinosa D, Soria JM. Antithrombin Cambridge II (A384S): an underestimated genetic risk 
factor for venous thrombosis. Blood. 2007;109:4258-4263. 
14. Austin H, De Staercke C, Lally C, Bezemer ID, Rosendaal FR, Hooper WC. New gene variants associated with 
venous thrombosis: a replication study in White and black Americans. J Thromb Haemost. 2011;9:489-495. 
15.  Bezemer ID, Bare LA, Doggen CJ, Arellano AR, Tong C, Rowland CM, Catanese J, Young BA, Reitsma PH, 
Devlin JJ, Rosendaal FR. Gene variants associated with deep vein thrombosis. JAMA. 2008;299:1306-1314. 
16. De Haan HG, Bezemer ID, Doggen CJM, Le Cessie S, Reitsma PH, Arellano AR, Tong CH, Devlin JJ, Bare LA, 
Rosendaal FR, Vossen CY. Multiple SNP testing improves risk prediction of first venous thrombosis. Blood. 
2012;120:656-663. 
17. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal, FR, Vos HL, Bertina RM. Genetic variation 
in the fibrinogen gamma gene increases the risk of deep venous thrombosis by reducing plasma fibrinogen gamma levels. 
Blood. 2005;106:4176-7183. 
18.  Grünbacher G, Weger W, Max-Neuhold E, Pilger E, Köppel H, Wascher T, März W, Renner W. The fibrinogen 
gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis. Thromb Res. 2007;121:33-36. 
19.  Morange PE, Oudot-Mellakh T, Cohen W, Germain M, Saut N, Antoni G, Alessi MC, Bertrand M, Dupuy AM, 
Letenneur L, Lathrop M, Lopez LM, Lambert JC, Emmerich J, Amouyel P, trégoüet DA. KNG1 ile581Thr and 
susceptibility to venous thrombosis. Blood. 2011;117:3692- 3694. 
 20. Arellano AR, Bezemer ID, Tong CH, Catanese JJ, Devlin JJ, Reitsma PH, Bare LA, Rosendaal FR. Gene variants 
associated with venous thrombosis: confirmation in the MEGA study. J Thromb Haemost. 2010;8:1132-1134. 
21. Austin H, De Staercke C, Lally C, Bezemer ID, Rosendaal FR, Hooper WC. New gene variants associated with 
venous thrombosis: a replication study in White and black Americans. J Thromb Haemost. 2011;9:489-495. 
 
